Oleg Gluz, MD, Evang. Krankenhaus “”Bethesda”” Klinik, Mönchengladbach, Germany, talks on treatment de-escalation approaches in triple-negative breast cancer (TNBC), highlighting the role of clinical markers, sensitivity to chemotherapy and the immune microenvironment can help guide decision-making in early TNBC. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.